A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for maintenance
Latest Information Update: 08 Jul 2023
At a glance
- Drugs Bortezomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Melphalan; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms Total Therapy III
- 06 Jun 2023 Results assessing follow up of MM trials (TT1 (NCT00580372), TT2 (NCT00083551), TT3a (NCT00081939) and TT3b (NCT00572169)) and reporting to date with RSRs to assess for curability,resented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 07 Dec 2007 Status changed from recruiting to in progress.
- 02 Sep 2005 New trial record.